Brainstorm Cell
BCLI0.81004.39% ( +0.0341 )
Brainstorm Cell (BCLI)
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment...
- Open
- 0.7700
- High
- 0.8100
- Low
- 0.7700
- Prev. Close
- 0.7759
- Volume
- 11.06K
- Turnover
- 8.80K
- Avg Price
- 0.7958
- Bid/Ask Ratio
- --
- Amplitude
- 5.16%
- 52wk High
- 1.6900
- Volume Ratio
- 4.16
- Turnover Ratio
- 0.11%
Brainstorm Cell Analyst Rating
View MoreForecast & Rating
Feb 21, 2026Price forecast
$17.002025.00%
Forecast & RatingHold
1analysts
- Strong buy0.00%
- Buy0.00%
- Hold100.00%
- Sell0.00%
- Strong sell0.00%
News
- StockTitan · 2 days ago, 06:28 AM
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027 | LNAI Stock News
- PUBT · Jul 30 at 04:08 PM
BrainStorm names ex-FDA official Peter Pitts executive chairman, Frenkel becomes senior adviser
- StockTitan · May 28 at 12:15 AM
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration | LNAI Stock News
- StockTitan · May 27 at 10:45 PM
BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors | BCLI Stock News
- Earnings Watch · May 15 at 04:02 PM
Brainstorm Cell | 8-K: FY2026 Q1 Revenue: USD 0
- StockTitan · May 15 at 07:05 AM
BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update | BCLI Stock News
